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Abstract Members of the mitochondrial carrier family trans-
port compounds over the inner mitochondrial membrane to link
the biochemical pathways in the cytosol with those in the mito-
chondrial matrix. X-ray crystallography has recently provided
us with the ¢rst atomic model of the bovine ADP/ATP carrier,
which is a member of this family. The structure explains the
typical three-fold sequence repeats and signature motif of mito-
chondrial carriers. However, the carrier was crystallised as a
monomer in detergent, which is inconsistent with the consensus
that mitochondrial carriers exist as homo-dimers. The projec-
tion structure of the yeast ADP/ATP carrier by electron crys-
tallography shows that carriers could form homo-dimers in the
membrane.
& 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Energy-generating pathways such as the citric acid cycle
and fatty acid L-oxidation are carried out inside mitochondria
to couple the production of NADH to oxidative phosphory-
lation. Mitochondria are also required for the synthesis and
degradation of amino acids (urea cycle), the synthesis of iron^
sulphur clusters and haem, and the generation of heat by
dissipation of the proton gradient. In addition, mitochondria
replicate mitochondrial DNA, and transcribe and translate
mitochondrial mRNA. To carry out these pathways, solutes
have to be continuously exchanged between the mitochondrial
matrix and the cytoplasm. Members of the mitochondrial
carrier family facilitate many of the transport steps over the
inner mitochondrial membrane.
When the ¢rst amino acid sequences of mitochondrial car-
riers became available [1^4], it was clear that the carriers form
a well-de¢ned family [5,6]. One de¢ning feature of the carriers
is the so-called tripartite structure, consisting of three homol-
ogous sequence repeats of about 100 amino acid residues
each, which was ¢rst noted in the published sequence of the
bovine ADP/ATP carrier [6] (Fig. 1). The carriers also have a
signature motif, which contains the P-X-[D/E]-X-X-[R/K] se-
quence and is conserved in all members of the family and in
all three repeats (Prosite PS50920) (Fig. 1). The general con-
sensus in the ¢eld is that the carriers are functional as homo-
dimers based on size exclusion chromatography [7^9], equilib-
rium sedimentation [7,8], neutron scattering [10], native gel
electrophoresis [9] and experiments with cross-linkers [11,12]
or tagged monomers [13].
The typical three-fold sequence repeats and signature motif
of mitochondrial carriers make it relatively easy to retrieve
sequences of mitochondrial carriers from genome databases.
Mitochondria of eukaryotes contain typically between 35 and
55 di¡erent carriers, which are all encoded by genomic DNA.
Not all members of the mitochondrial carrier family are
actually targeted to mitochondria. An adenine nucleotide car-
rier has been characterised in yeast peroxisomes [14] and an
ADP-glucose carrier in amyloplasts, which are modi¢ed chlor-
oplasts involved in starch storage [15]. An ADP/ATP carrier
was also identi¢ed in hydrogenosomes, which are organelles
that carry out anaerobic energy metabolism using protons as
terminal electron acceptors to produce hydrogen [16]. How-
ever, no homologues of mitochondrial carriers have ever been
found in prokaryotes or archaea, meaning that they are a
uniquely eukaryotic invention.
2. The role of mitochondrial carriers in cellular metabolism
The human genome likely encodes 48 di¡erent mitochon-
drial carriers. If one assumes that transporters with very high
sequence identity have similar functions then it is estimated
that there are 39 possible functions in total, of which approx-
imately a third have now been assigned.
Several strategies have been applied for the identi¢cation of
carriers. Carriers have been over-expressed in inclusion bodies
in Escherichia coli, puri¢ed and reconstituted into liposomes
for characterisation by transport assays [17]. Another ap-
proach uses the over-expression of carriers in yeast mitochon-
dria, followed by puri¢cation and reconstitution (e.g. [18]). An
alternative method was recently developed using the nisin ex-
pression system of the Gram-positive Lactococcus lactis [19].
The advantage of this system is that the carrier can often be
directly characterised in whole cells or membrane vesicles
without the need for puri¢cation and reconstitution. Finally,
the development of genetic techniques has allowed the con-
struction of speci¢c deletion strains or gene knock-outs. The
physiological characterisation of isolated mitochondria can be
a good strategy to obtain clues about the possible function of
the carrier, but since the deletion can cause rather complicated
add-on e¡ects the substrate speci¢city can never be assigned
with con¢dence in that way.
In the following sections the involvement of mitochondrial
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carriers in mitochondrial DNA replication, metabolic energy
generation and amino acid metabolism will be discussed, fo-
cussing mainly on the mammalian mitochondrion. Infor-
mation will be used that was obtained for yeast and plant
mitochondrial carriers to indicate where possibly essential
information is still missing. For details and references on
the biochemical properties of the carriers and their involve-
ment in diseases the reader is referred to a recent review by
Palmieri [20].
2.1. Metabolic energy generation
The degradation of sugars by glycolysis in the cytosol yields
pyruvate as the ¢nal product (Fig. 2). Pyruvate is transported
into the mitochondrion for the conversion to acetyl-CoA. The
human pyruvate transporter has not been identi¢ed, but the
yeast carrier was reported to be encoded by gene YIL006w
[21]. The assignment is based on the characterisation of pyru-
vate transport in mitochondria isolated from deletion strains,
but needs to be con¢rmed by using puri¢ed protein in a re-
constituted system. For conversion of pyruvate to acetyl-CoA,
the mitochondrion also requires the accumulation of coen-
zyme A itself. In yeast, the carrier might be encoded by
YHR002w, because it was found to be essential for the main-
tenance of coenzyme A levels [22]. The human isoform,
known as the Graves’ disease carrier, complements the phe-
notype in yeast, but the substrate speci¢city of these carriers
has not been determined directly. The conversion of pyruvate
to acetyl-CoA, which is catalysed by pyruvate dehydrogenase,
also requires several other co-factors like lipoamide, thiamine
pyrophosphate, NADþ and FAD. Yeast carriers have been
described for thiamine pyrophosphate [23] and FAD [24],
while plants might have a transporter for NADþ [25], but it
has not established whether it belongs to the mitochondrial
carrier family.
Acetyl-CoA enters the citric acid cycle, which produces re-
ducing equivalents and GTP (Fig. 2). Several human carriers
are involved in exchanging intermediates of the citric acid
cycle with the cytosol such as the dicarboxylate [26], tricar-
boxylate carrier [27] and oxoglutarate/malate carrier [28].
Yeast mitochondria also contain a fumarate/succinate carrier
[29] and an oxaloacetate carrier [30].
The complexes of the respiratory chain generate a gradient
of protons across the mitochondrial inner membrane and use
reducing equivalents as electron donors (Fig. 2). The proton
motive force is used by the ATP synthase to synthesise ATP
from ADP and inorganic phosphate [31]. The ADP/ATP car-
rier catalyses the exchange of cytosolic ADP for ATP synthe-
sised in the mitochondrial matrix and thereby replenishes the
Fig. 1. Topology model of the yeast ADP/ATP carrier (AAC3). The black areas indicate the regions that were predicted to be transmembrane
on the basis of hydropathy pro¢ling. The dark grey areas were proposed extensions of the K-helices [44] based on the simple assumption that
all conserved regions were likely to have K-helical structure. The light grey regions show the additional amino acid residues found in the experi-
mentally determined K-helices based on similarity with the structure of the bovine ADP/ATP carrier [45]. Red dotted lines indicate the borders
of the three sequence repeats of the tripartite structure. The amino acid identity and similarity between the repeats in AAC3 are approximately
20% and 50%. The regions with the signature motif are bordered by red bars. Residues with negative charges are indicated in red, those with
positive charges in blue and proline residues in green. The loops in the mitochondrial matrix are numbered M1, M2 and M3, the cytoplasmic
loops C1, C2, C3 and C4. The helices are indicated with Roman numerals on the left hand side of the helices.
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eukaryotic cell with metabolic energy [32]. The adenine nucle-
otide exchange is strictly equimolar, meaning that the total
adenine nucleotide pool in the matrix will not change as a
consequence [32]. When the mitochondrion divides during
cell division the total adenine nucleotide content would halve
and the mitochondrion therefore needs a carrier to replenish
the adenine nucleotide pools. The ATP-Mg/Pi carrier could
ful¢l this role, but the gene encoding the carrier has not been
identi¢ed to con¢rm it belongs to the family [33]. The dicar-
boxylate [26] and phosphate carriers [3] are important for the
maintenance of inorganic phosphate levels in the mitochon-
drial matrix.
Mitochondria also play a central role in the oxidation of
fatty acids derived from lipid breakdown, which is a very
e⁄cient source of metabolic energy (Fig. 2). Fatty acid chains
are transferred from coenzyme A to carnitine by carnitine
palmitoyltransferase in the outer mitochondrial membrane.
The carnitine/acyl-carnitine carrier transports acyl-carnitine
into the mitochondrial matrix in exchange for free carnitine,
which is generated when the acyl chains are transferred back
to coenzyme A [34]. Acyl-CoA then enters fatty acid L-oxida-
tion for the cyclical breakdown of the carbon chain. In each
cycle, FADH2 and NADH are produced as well as acetyl-
CoA by removal of two carbon atoms from the chain. Ace-
tyl-CoA enters the citric acid cycle for the production of addi-
tional reducing equivalents, which are all used in oxidative
phosphorylation for the production of ATP. An important
head group of lipids, choline, is also transported into mito-
chondria, where it is oxidised to betaine by an NAD-linked
enzyme [35], but it is unknown whether this transport step is
carried out by a mitochondrial carrier. Finally, the proton
gradients generated by the electron chain can be dissipated
by the uncoupling protein to produce heat [36].
2.2. Amino acid metabolism
Mitochondria are also important in the synthesis and deg-
radation of amino acids (Fig. 2). Ammonium, which is de-
rived from the conversion of glutamate to oxo-glutarate or
glutamine to glutamate, is ¢xed as carbamoyl-phosphate in
the mitochondrial matrix. Carbamoyl-phosphate reacts with
ornithine to form citrulline, which is transported out of mi-
tochondria by the citrulline/ornithine exchanger. Citrulline en-
ters the urea cycle, which leads to the production of urea and
ornithine as the ¢nal products. Ornithine is used as a substrate
in the exchange for citrulline [37]. The urea cycle is also im-
portant for the metabolism of arginine, aspartate and aspar-
agine (Fig. 2).
Glutamine is transported into the mitochondrial matrix by
the glutamine transporter, but the corresponding gene has not
been identi¢ed meaning that it might not be a member of the
family. Glutamate is transported into the mitochondrion by
the glutamate transporter [38] and the aspartate/glutamate ex-
changer [39]. The aspartate/glutamate exchanger [39] and the
oxoglutarate/malate carrier [28] are also part of the malate^
aspartate shuttle that is used for the removal of reducing
equivalents from the cytosol by a series of conversions and
Fig. 2. Role of mitochondrial carriers in mitochondrial and cellular metabolism. A schematic representation of the inner membrane of a mam-
malian mitochondrion with the ATP synthase, the complexes of the respiratory chain and mitochondrial carriers. The permeable outer mito-
chondrial membrane is not shown. Red arrows indicate the metabolic pathways, which are simpli¢ed to emphasise key metabolites. Co-factors
and high-energy intermediates are indicated in green. Note that the same metabolites appear at di¡erent sites, meaning that in principle the cor-
responding pathways are linked. Blue arrows indicate the directionality of the transport steps over the inner mitochondrial membrane as carried
out by the membrane proteins. The human transporters of CoA, glutamine, FAD, NADþ, and pyruvate are marked with a question mark, be-
cause it is currently unknown whether they belong to the mitochondrial carrier family.
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transport steps (Fig. 2). The transport of glutamate could also
play a central role in the metabolism of proline and histidine.
Lysine and tryptophan are broken down to oxoadipate,
which is transported to the mitochondrial matrix in exchange
for oxoglutarate [40]. Oxoadipate is broken down to two ace-
tyl-CoAs with the production of reducing equivalents. Acetyl-
CoA enters the citric acid cycle, which leads to the production
of oxoglutarate, the other substrate in the transport exchange.
Alanine, serine and cysteine are degraded in the cytosol to
pyruvate, which enters the mitochondrion via the pyruvate
carrier, while phenylalanine and tyrosine are broken down
to malate, which is transported by the dicarboxylate carrier
[26]. The human transporter for folate, which is used for in-
terconversion of glycine and serine in the mitochondrial ma-
trix, has been described and is a member of the mitochondrial
carrier family [41].
2.3. Mitochondrial DNA replication
Mitochondria have their own DNA, which encodes several
proteins of the electron transport chain complexes and ATP
synthase. Mitochondria have a deoxynucleotide carrier that
could supply mitochondria with deoxynucleotides for mito-
chondrial DNA replication [42]. For methylation of DNA,
RNA and proteins, mitochondria use S-adenosylmethionine,
which is translocated by a speci¢c transporter of the mito-
chondrial carrier family [43].
3. The structure of mitochondrial carriers
In 2003, the projection structure of the yeast ADP/ATP
carrier [44] and the atomic model of the bovine ADP/ATP
carrier were published [45]. Both e¡orts concentrated on the
ADP/ATP carrier, because the carrier is a good target for
structural work. First, the carrier is one of the best studied
and characterised members of the mitochondrial carrier fam-
ily (reviewed in [46^48]). Second, the carrier is usually the
most abundant transporter in mitochondria, which aids the
isolation and puri¢cation of starting material for crystallisa-
tion trials. Third, the carrier can be inhibited in two distinct
conformational states, which are reasonably stable in deter-
gents. The carrier binds carboxy-atractyloside or atractyloside
in the cytoplasmic or c-state and bongkrekic acid in the ma-
trix or m-state (reviewed in [47,48]).
The projection structure was obtained using only a few mil-
ligrams of over-expressed yeast ADP/ATP carrier (AAC3)
[44]. The carrier was inhibited by atractyloside, puri¢ed in
dodecyl-maltoside and reconstituted into two-dimensional
crystals. Images of frozen hydrated crystals were recorded
by electron cryo-microscopy and the projection structure
was calculated to 8 AQ resolution. It was clear from the pro-
jection structure that the AAC3 molecule had pseudo three-
fold symmetry in agreement with the three-fold sequence re-
peats that are typical of members of the mitochondrial carrier
family (Fig. 3A). The projection structure also showed that
the carrier was most likely a bundle of six transmembrane K-
helices rather than an integrated bundle of 12. This was a
surprising ¢nding in view of the general consensus that mito-
chondrial carriers are homo-dimers in structure and function
[7^13]. This meant that dimer formation could only occur via
association of two structurally separate monomers. Interest-
ingly, the two-dimensional crystals contained homo-dimers,
which seem to be the main crystallising unit in two di¡erent
crystal forms. The pore in the centre of the monomer was
clearly the most likely site for translocation of adenine nucleo-
tides [44].
The predicted K-helices based on the hydropathy pro¢ling
alone would be too short to form a bundle of six tilted K-heli-
ces. Therefore, a new topology model was proposed based on
the simple assumption that well-conserved regions in mito-
chondrial carriers were likely to form secondary structure
(Fig. 1). Two predictions were made: (i) the region of the
signature motif would be part of the odd-numbered trans-
membrane K-helices and (ii) short K-helices would be present
in the matrix loops at the N-terminal side of the extended
even transmembrane K-helices (Fig. 1) [44].
Many of these issues were entirely resolved by the atomic
structure of the bovine ADP/ATP carrier, which was solved to
2.2 AQ [45]. The ADP/ATP carrier is the most abundant trans-
porter in bovine heart mitochondria and was puri¢ed in the
detergent lauryl-amidodimethyl-propylaminoxide (references
in [45]), which was ¢rst used by Klingenberg for this purpose
[49]. Key to success of the crystallisations was the removal of
excess detergent by BioBeads in a controlled manner [50]. The
carrier was crystallised in complex with the inhibitor carboxy-
atractyloside, which locks the carrier in the cytoplasmic state
like atractyloside [45].
The structure explains two general sequence features of mi-
tochondrial carriers in molecular detail : the three internal se-
quence repeats and the conservation of the signature motif.
The main structural fold is indeed a six K-helical bundle with
pseudo three-fold symmetry (Fig. 3B,C). The fold of the three
repeats in the structure is very similar with root-mean-square
deviations of less than 2 AQ [45]. The prolines of the signature
motif induce a sharp kink in the odd-numbered K-helices,
which close the central pore of the K-helical bundle on the
matrix side (Fig. 3B,C). These particular helices are held to-
gether by salt bridges and hydrogen bonds, which are formed
by the charged residues of the three signature motifs (Fig. 3C)
[45]. The existence of charge pair networks had been predicted
through the analysis of second site revertants in yeast [51]. It
is possible to see how a rearrangement of these bonds might
cause opening of the carrier on the matrix side when the
molecule changes conformation. The structure also provides
detailed information on how carboxy-atractyloside is bound
in the open cavity that is formed by the bundle [45]. Interest-
ingly, residues involved in binding of carboxy-atractyloside
are also involved in the charged pair network, suggesting
that substrate binding and opening of the central pore might
be related events.
All features of the projection map of the yeast ADP/ATP
carrier can be explained by the structure of the bovine ADP/
ATP carrier. The asymmetric feature in the core of the mol-
ecule can now be attributed to atractyloside. The surprising
¢nding of the X-ray structure was the absence of dimers in the
crystals, which cannot be easily explained in view of earlier
observations [7^13]. Using the bovine structure we are carry-
ing out a detailed analysis of the crystal packing in the mem-
brane to study the interface of the putative dimer seen in the
projection structure.
So what more needs to be done to advance our understand-
ing of the transport cycle in structural terms? The inhibitors
that were used in both studies are not structural analogues of
adenine nucleotides, so we still do not know where exactly
ADP binds. However, the inhibitors do prevent ADP binding,
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indicating that the binding sites may partially overlap. Muta-
genesis has identi¢ed several residues important for the bind-
ing of adenine nucleotides and some of these are indeed in-
volved in the binding of carboxy-atractyloside too [45]. This,
however, means that the inhibited state of the carrier may not
resemble the empty cytoplasmic state of the carrier, because
the inhibitor is partially bound to the binding site. It may also
not resemble the nucleotide binding state either, because the
binding of ADP must lead to a change in conformation in the
transport cycle, which is clearly prevented in the inhibited
state. How ATP binds to the matrix state of the carrier is
of course not known at all. The problem for structural
work is that the uninhibited states are quite unstable in de-
tergent. The use of structural analogues of adenine nucleotides
and/or the selective mutagenesis of the putative binding sites
could be a way to obtain stable intermediates for structure
determination.
The structure does not provide insight into the dynamic
changes that need to occur when the transporter changes
from cytosolic to matrix state either. Therefore, another im-
portant target of structural work is the bongkrekate-inhibited
state, which may resemble the carrier with the binding site
open to the matrix side, but is in e¡ect also an arti¢cial state.
The transition state between the two conformations is also
intriguing. It is very unlikely that the carrier transforms into
a channel-like conformation as suggested [45], since this may
lead to the in£ux of protons during translocation.
What about the oligomeric state of the carrier and its rela-
tion to conformational changes? It is clear that mitochondrial
carriers are structurally monomers in the membrane [44] and
Fig. 3. Projection map of the yeast ADP/ATP carrier and atomic model of the bovine ADP/ATP carrier. A: The projection map of yeast
AAC3 with atractyloside bound, which was calculated from merged amplitudes and phases of ¢ve independent lattices with p22121 symmetry
imposed [44]. The unit cell is displayed with the a-axis (42.5 AQ ) horizontal and the b-axis (172.1 AQ ) vertical. Solid lines indicate density above
the mean, while negative contours are shown as dotted lines. At this density cut-o¡, side chain densities are not shown. The bold dotted lines
in the equilateral triangles indicate the approximate area that the side chains would occupy. The two molecules of the putative homo-dimer are
shown in blue and red. B,C: Membrane (B) and matrix (C) view of the bovine ADP/ATP carrier model with carboxy-atractyloside bound,
based on the coordinates provided by Pebay-Peyroula and colleagues (1okc) [45]. Only the secondary structure elements are shown and the car-
boxy-atractyloside molecule is omitted. The conserved elements of the ¢rst repeat are shown in red, of the second in yellow and of the third in
blue. The white bars indicate the approximate position of the inner mitochondrial membrane. The atoms of the proline residues of the signa-
ture motif are depicted in green spheres and the salt bridge residues in CPK coloured spheres. The models are shown in perspective. Also
shown is the schematic representation of the charged pair relay by the signature motif of the ADP/ATP carrier. The ¢gure was made with
Yasara.
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in detergent [45], but they could associate to form a dimer as
suggested [7^13]. One important implication of the homo-
dimer model is that the two halves could coordinate the
change in conformation in a cooperative manner to ensure
the equimolar exchange of adenine nucleotides [52]. This
means that the intact homo-dimer needs to be crystallised
with the two associated monomers in di¡erent conformational
states of the transport cycle. It is clear that there is still a
considerable amount of work to do before we understand
how these transporters work in structural detail.
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